myNEO

Ottergemsesteenweg-Zuid 808 B511

9000 Gent

BE

myNEO

Foundation date

01/12/2018

Sector

#Biotechnology / R&D Services

Subsector

Therapeutic areas

myNEO is a distinguished Belgian biotech powerhouse dedicated to pioneering breakthrough immunotherapies tailored to target diverse tumor profiles. myNEO's discovery platform leverages immuno-genomic datasets to identify tumor alterations and unveil promising and largely untapped immunotherapeutic targets. In vivo studies underscore myNEO's prowess in identifying effective tumor targets. myNEO is now advancing development of its proprietary 'camyotopes', a class of long non-coding RNAs that shows selective translation in tumor tissue and a robust immunogenic multi-targeted response against the tumor. The lead program CAMYO-01 will validate the MOA of the camyotopes in a CRC phase I/II trial, while simultaneously expanding the development pipeline to other indications.

Upcoming events

Latest news

  • Mithra reaches milestone in estetrol skin study

    Tuesday April 9th 2024

  • Stool transplant shows promise for Parkinson's disease

    Thursday April 4th 2024

  • Strong data from Sequana Medical's DSRĀ® proof-of-concept studies in heart failure published in European Journal of Heart Failure

    Wednesday April 3rd 2024